Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17791781 | 0.92 | CHRNB2 (0.44) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL22746304 | 0.82 | CHRM2 (0.42) | CYP2D6CYP2C19CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL18884045 | 0.80 | CHRNB2 (0.44) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL19689032 | 0.79 | MEN1 (0.39) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL7474868 | 0.78 | CHRNB2 (0.53) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL8100097 | 0.76 | CHRNB2 (0.47) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL7241275 | 0.76 | MEN1 (0.40) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL10816950 | 0.76 | MEN1 (0.40) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL11114694 | 0.76 | MEN1 (0.40) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL29274356 | 0.76 | MEN1 (0.40) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115386080-B | Method for preparing polyether modified siloxane | 江西蓝星星火有机硅有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| EP-4245744-A2 | CHEMICALLY CLEAVABLE GROUP | Tagworks Pharmaceuticals B.V. (NL) | 2023-09-20 | — | — | EP | disclosed |
| CN-115386080-B | Method for preparing polyether modified siloxane | 江西蓝星星火有机硅有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-2922574-B1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B V (NL) | 2023-05-17 | — | — | EP | disclosed |
| CN-115386080-A | Method for preparing polyether modified siloxane | 江西蓝星星火有机硅有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-2709667-B1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B V (NL) | 2022-04-13 | — | — | EP | disclosed |
| EP-3973993-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | Tagworks Pharmaceuticals B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| EP-2709666-B1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS NV (NL) | 2021-07-14 | — | — | EP | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081303-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081301-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081300-A1 | CHANNEL PROTEIN ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081299-A1 | ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | MEN1 565/4885CYP2D6 343/4885CYP2C19 331/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | MEN1 1926/4885CYP2D6 65/4885CYP2C19 69/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | MEN1 3386/4885CYP2D6 107/4885CYP2C19 351/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | MEN1 3386/4885CYP2D6 107/4885CYP2C19 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.